Kaken Pharmaceutical

4521 · TSE

Public Market Listing

4521TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Kaken Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Seladelpar(Livdelzi)
Approved
PPAR-deltaSmall molecule
Cholestatic Liver Disease
Primary Biliary Cholangitis
Phase 3
TYK2Small molecule
PsoriasisSystemic Lupus Erythematosus

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
EnvudeucitinibPhase 2Plaque Psoriasis
Est. primary completion 2027-12-01 · NCT05739435 · CT.gov ↗
What to watch
2028 (3)
November 2028 (2)
Seladelpar · LivdelziPhase 3Primary Biliary Cirrhosis
Est. primary completion 2028-11 · NCT03301506 · CT.gov ↗
What to watch
EnvudeucitinibPhase 3Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Est. primary completion 2028-11 · NCT06846541 · CT.gov ↗
What to watch
December 2028 (1)
Seladelpar · LivdelziPhase 2Primary Biliary Cholangitis
Est. primary completion 2028-12 · NCT07841977 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Seladelpar · LivdelziPhase 3Primary Biliary Cholangitis
Est. primary completion 2030-08 · NCT06051617 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 September 2026Topline resultEnvudeucitinibPhase 2b LUMUS (NCT05966480) in SLE missed its primary and secondary endpoints
Alumis Inc. · Source ↗
2 June 2026Topline resultSeladelparIDEAL (NCT06060665) Phase 3 met its primary endpoint
Gilead Sciences, Inc. · Source ↗
6 January 2026Topline resultEnvudeucitinibONWARD1 and ONWARD2: envudeucitinib met all primary and secondary endpoints
Alumis · Source ↗

Financial reports

No financial reports recorded.